Insider Trading Activity Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) – Director Bought 25,000 shares of Stock

ME Staff
-
0

Insider Trading Activity For Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)

Stephen M Dow , Director of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) reportedly Bought 25,000 shares of the company’s stock at an average price of 10 for a total transaction amount of $250,000.00 SEC Form

Insider Trading History For Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)

  • On 5/13/2014 West 8 Limited Partne Ventures, Major Shareholder, bought 250,000 with an average share price of $10.00 per share and the total transaction amounting to $2,500,000.00.View SEC Filing
  • On 5/13/2014 Alan Bruce Montgomery, Director, bought 3,000 with an average share price of $10.00 per share and the total transaction amounting to $30,000.00.View SEC Filing
  • On 5/13/2014 A/S Novo, Insider, bought 550,000 with an average share price of $10.00 per share and the total transaction amounting to $5,500,000.00.View SEC Filing
  • On 11/24/2014 Jeffrey T L Smith, VP, sold 29,090 with an average share price of $16.08 per share and the total transaction amounting to $467,767.20.View SEC Filing
  • On 1/26/2015 Randall C Schatzman, CEO, sold 36,422 with an average share price of $27.93 per share and the total transaction amounting to $1,017,266.46.View SEC Filing
  • On 1/26/2015 Mark James Litton, Insider, sold 5,200 with an average share price of $28.03 per share and the total transaction amounting to $145,756.00.View SEC Filing
  • On 1/26/2015 Jeffrey T L Smith, VP, sold 2,700 with an average share price of $27.89 per share and the total transaction amounting to $75,303.00.View SEC Filing

    • Analyst Ratings For Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)
    These are 1 Hold Rating, 9 Buy Ratings .
    The current consensus rating for Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) is Buy (Score: 2.90) with a consensus target price of $39.40 , a potential (241.13% upside)

    Analyst Ratings History For Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)

    • On 9/13/2016 J P Morgan Chase & Co Initiated Coverage of rating Overweight with a price target of $40.00
    • On 9/30/2016 Brean Capital Initiated Coverage of rating Buy with a price target of $45.00
    • On 12/9/2016 BMO Capital Markets Reiterated Rating Outperform with a price target of $42.00
    • On 4/17/2017 Jefferies Group LLC Reiterated Rating Buy with a price target of $43.00
    • On 6/12/2017 Leerink Swann Reiterated Rating Outperform with a price target of $32.00
    • On 6/28/2017 Credit Suisse Group Downgraded rating Outperform to Neutral with a price target of $30.00 to $17.00
    • On 6/28/2017 Piper Jaffray Companies Reiterated Rating Overweight with a price target of $47.00

    Recent Trading Activity for Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)
    Shares of Alder BioPharmaceuticals, Inc. closed the previous trading session at 11.55 down -0.30 -2.53% with 1,653,457 shares trading hands.